Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GP MDI versus FF MDI crossover FRI study in moderate to severe COPD
2015-001744-11Phase 3Completed
- Sponsor
- Pearl Therapeutics
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of glycopyrronium and formoterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Pearl Therapeutics. Primary endpoint: Specific image-based airway volumes and resistance. Started Oct 2016; status: completed.
02
Drugs
glycopyrroniumformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2015-001744-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001744-11.